Free Trial
→ Something strange going on at Mar-a-Lago (From Brownstone Research) (Ad) Buy TLPPF Stock  Free TLPPF Stock Alerts

Telix Pharmaceuticals (TLPPF) Financials

Telix Pharmaceuticals logo
$16.46 -0.49 (-2.90%)
As of 04/17/2025 11:39 AM Eastern
Compare
Annual Income Statements for Telix Pharmaceuticals

Annual Income Statements for Telix Pharmaceuticals

This table shows Telix Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -71 2.83 31
Consolidated Net Income / (Loss)		 -71 3.56 31
Net Income / (Loss) Continuing Operations		 -68 2.83 47
Total Pre-Tax Income 		-67 2.11 35
Total Operating Income		 -63 1.99 51
Total Gross Profit		 65 215 315
Total Revenue		 109 319 484
Operating Revenue		 109 344 484
Total Cost of Revenue		 44 141 169
Operating Cost of Revenue		 44 141 169
Total Operating Expenses		 112 176 254
Selling, General & Admin Expense		 32 51 80
Marketing Expense		 25 34 53
Research & Development Expense		 55 88 120
Total Other Income / (Expense), net		 -17 -0.61 -11
Interest Expense		 4.55 - 23
Interest & Investment Income		 0.00 -0.61 6.72
Other Income / (Expense), net		 -13 - 5.02
Income Tax Expense		 3.71 -1.45 3.80
Basic Earnings per Share		 ($22.80) - $9.32
Weighted Average Basic Shares Outstanding		 - - 334.72M
Diluted Earnings per Share		 ($22.80) - $8.94
Weighted Average Diluted Shares Outstanding		 - - 334.72M
Weighted Average Basic & Diluted Shares Outstanding		 - - 334.72M

Quarterly Income Statements for Telix Pharmaceuticals

No quarterly income statements for Telix Pharmaceuticals are available.

Annual Cash Flow Statements for Telix Pharmaceuticals

This table details how cash moves in and out of Telix Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Change in Cash & Equivalents		 81 38 338
Net Cash From Operating Activities		 -16 -279 27
Net Cash From Continuing Operating Activities		 -16 -279 2.05
Net Income / (Loss) Continuing Operations		 0.00 0.00 0.00
Changes in Operating Assets and Liabilities, net		 - - 2.05
Net Cash From Investing Activities		 84 317 -84
Net Cash From Continuing Investing Activities		 84 317 -81
Purchase of Property, Plant & Equipment		 - - -21
Acquisitions		 - - -19
Purchase of Investments		 - - -41
Net Cash From Financing Activities		 13 0.00 395
Net Cash From Continuing Financing Activities		 13 0.00 395
Repayment of Debt		 - - -1.94
Issuance of Debt		 - - 396
Other Financing Activities, net		 13 0.00 0.62

Quarterly Cash Flow Statements for Telix Pharmaceuticals

No quarterly cash flow statements for Telix Pharmaceuticals are available.

Annual Balance Sheets for Telix Pharmaceuticals

This table presents Telix Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2023 2024
Total Assets		 277 938
Total Current Assets		 159 568
Cash & Equivalents		 84 439
Accounts Receivable		 44 86
Inventories, net		 12 24
Current Deferred & Refundable Income Taxes		 5.23 5.88
Other Current Assets		 13 13
Plant, Property, & Equipment, net		 16 28
Plant, Property & Equipment, gross		 16 28
Total Noncurrent Assets		 103 342
Long-Term Investments		 8.37 35
Intangible Assets		 75 257
Noncurrent Deferred & Refundable Income Taxes		 14 29
Other Noncurrent Operating Assets		 5.40 21
Total Liabilities & Shareholders' Equity		 247 836
Total Liabilities		 176 586
Total Current Liabilities		 113 205
Short-Term Debt		 0.66 12
Accounts Payable		 56 87
Current Deferred & Payable Income Tax Liabilities		 13 30
Other Current Liabilities		 8.31 9.08
Total Noncurrent Liabilities		 63 382
Long-Term Debt		 5.61 341
Capital Lease Obligations		 5.24 5.04
Noncurrent Deferred & Payable Income Tax Liabilities		 0.00 5.80
Other Noncurrent Operating Liabilities		 14 11
Total Equity & Noncontrolling Interests		 102 351
Total Preferred & Common Equity		 145 336
Total Common Equity		 145 336
Common Stock		 305 369
Retained Earnings		 -180 -132
Other Equity Adjustments		 20 98

Quarterly Balance Sheets for Telix Pharmaceuticals

No quarterly balance sheets for Telix Pharmaceuticals are available.

Annual Metrics and Ratios for Telix Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Telix Pharmaceuticals' official financial filings.

Metric 2022 2023 2024
Growth Metrics		 - - -
Revenue Growth		 0.00% 193.13% 51.69%
EBITDA Growth		 0.00% 102.64% 2,709.41%
EBIT Growth		 0.00% 102.64% 2,709.41%
NOPAT Growth		 0.00% 107.66% 1,248.70%
Net Income Growth		 0.00% 105.02% 767.74%
EPS Growth		 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 0.00% -1,631.30% 109.55%
Free Cash Flow Firm Growth		 0.00% 0.00% -102.39%
Invested Capital Growth		 0.00% 0.00% 243.41%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00%
Profitability Metrics		 - - -
Gross Margin		 59.29% 67.22% 65.08%
EBITDA Margin		 -69.13% 0.62% 11.52%
Operating Margin		 -57.42% 0.62% 10.49%
EBIT Margin		 -69.13% 0.62% 11.52%
Profit (Net Income) Margin		 -65.01% 1.11% 6.37%
Tax Burden Percent		 105.53% 168.80% 89.05%
Interest Burden Percent		 89.10% 106.08% 62.11%
Effective Tax Rate		 0.00% -68.80% 10.95%
Return on Invested Capital (ROIC)		 0.00% 7.16% 21.77%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 2.03% 98.27%
Return on Net Nonoperating Assets (RNNOA)		 0.00% -0.16% -8.14%
Return on Equity (ROE)		 0.00% 7.00% 13.63%
Cash Return on Invested Capital (CROIC)		 0.00% -192.84% -88.02%
Operating Return on Assets (OROA)		 0.00% 0.72% 9.19%
Return on Assets (ROA)		 0.00% 1.28% 5.08%
Return on Common Equity (ROCE)		 0.00% 9.95% 14.44%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 2.46% 9.20%
Net Operating Profit after Tax (NOPAT)		 -44 3.35 45
NOPAT Margin		 -40.20% 1.05% 9.34%
Net Nonoperating Expense Percent (NNEP)		 0.00% 5.13% -76.50%
Return On Investment Capital (ROIC_SIMPLE)		 - 2.96% 6.38%
Cost of Revenue to Revenue		 40.71% 44.28% 34.92%
SG&A Expenses to Revenue		 29.45% 15.86% 16.58%
R&D to Revenue		 50.40% 27.48% 24.85%
Operating Expenses to Revenue		 102.54% 55.09% 52.34%
Earnings before Interest and Taxes (EBIT)		 -75 1.99 56
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -75 1.99 56
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 0.00 1.40 15.36
Price to Tangible Book Value (P/TBV)		 0.00 2.90 65.97
Price to Revenue (P/Rev)		 1.85 0.63 10.64
Price to Earnings (P/E)		 0.00 71.40 166.96
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 1.40% 0.60%
Enterprise Value to Invested Capital (EV/IC)		 0.00 1.29 15.66
Enterprise Value to Revenue (EV/Rev)		 0.00 0.38 10.40
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 60.79 90.27
Enterprise Value to EBIT (EV/EBIT)		 0.00 60.79 90.27
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 36.01 111.39
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 189.33
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.11 1.02
Long-Term Debt to Equity		 0.00 0.11 0.99
Financial Leverage		 0.00 -0.08 -0.08
Leverage Ratio		 0.00 2.73 2.68
Compound Leverage Factor		 0.00 2.89 1.67
Debt to Total Capital		 0.00% 10.17% 50.47%
Short-Term Debt to Total Capital		 0.00% 0.58% 1.66%
Long-Term Debt to Total Capital		 0.00% 9.58% 48.81%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 127.74% 47.29%
Debt to EBITDA		 0.00 5.79 6.41
Net Debt to EBITDA		 0.00 -40.77 -2.08
Long-Term Debt to EBITDA		 0.00 5.46 6.20
Debt to NOPAT		 0.00 3.43 7.92
Net Debt to NOPAT		 0.00 -24.15 -2.56
Long-Term Debt to NOPAT		 0.00 3.23 7.66
Altman Z-Score		 0.00 1.16 6.26
Noncontrolling Interest Sharing Ratio		 0.00% -42.19% -5.95%
Liquidity Ratios		 - - -
Current Ratio		 0.00 1.41 2.78
Quick Ratio		 0.00 1.14 2.57
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 0.00 -90 -183
Operating Cash Flow to CapEx		 0.00% 0.00% 126.44%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -8.01
Operating Cash Flow to Interest Expense		 -3.53 0.00 1.17
Operating Cash Flow Less CapEx to Interest Expense		 -3.53 0.00 0.24
Efficiency Ratios		 - - -
Asset Turnover		 0.00 1.15 0.80
Accounts Receivable Turnover		 0.00 7.22 7.43
Inventory Turnover		 0.00 11.97 9.56
Fixed Asset Turnover		 0.00 20.19 22.21
Accounts Payable Turnover		 0.00 2.54 2.38
Days Sales Outstanding (DSO)		 0.00 50.55 49.16
Days Inventory Outstanding (DIO)		 0.00 30.50 38.20
Days Payable Outstanding (DPO)		 0.00 143.98 153.54
Cash Conversion Cycle (CCC)		 0.00 -62.93 -66.18
Capital & Investment Metrics		 - - -
Invested Capital		 0.00 94 322
Invested Capital Turnover		 0.00 6.82 2.33
Increase / (Decrease) in Invested Capital		 0.00 94 228
Enterprise Value (EV)		 0.00 121 5,039
Market Capitalization		 202 202 5,155
Book Value per Share		 $0.00 $8.50 $1.00
Tangible Book Value per Share		 $0.00 $4.10 $0.23
Total Capital		 0.00 113 710
Total Debt		 0.00 12 358
Total Long-Term Debt		 0.00 11 346
Net Debt		 0.00 -81 -116
Capital Expenditures (CapEx)		 0.00 0.00 21
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -37 -64
Debt-free Net Working Capital (DFNWC)		 0.00 47 375
Net Working Capital (NWC)		 0.00 46 363
Net Nonoperating Expense (NNE)		 27 -0.20 14
Net Nonoperating Obligations (NNO)		 0.00 -7.96 -30
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -11.72% -13.24%
Debt-free Net Working Capital to Revenue		 0.00% 14.63% 77.46%
Net Working Capital to Revenue		 0.00% 14.42% 75.03%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $9.32
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 334.72M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $8.94
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 334.72M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 334.72M
Normalized Net Operating Profit after Tax (NOPAT)		 -44 1.39 45
Normalized NOPAT Margin		 -40.20% 0.44% 9.34%
Pre Tax Income Margin		 -61.60% 0.66% 7.16%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 -16.54 0.00 2.44
NOPAT to Interest Expense		 -9.61 0.00 1.98
EBIT Less CapEx to Interest Expense		 -16.54 0.00 1.52
NOPAT Less CapEx to Interest Expense		 -9.61 0.00 1.06
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Telix Pharmaceuticals

No quarterly metrics and ratios for Telix Pharmaceuticals are available.

Frequently Asked Questions About Telix Pharmaceuticals' Financials

When does Telix Pharmaceuticals's fiscal year end?

According to the most recent income statement we have on file, Telix Pharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Telix Pharmaceuticals' net income changed over the last 2 years?

Telix Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of $30.87 million in 2024, falling from -$70.83 million in 2022. The previous period was $3.56 million in 2023.

What is Telix Pharmaceuticals's operating income?
Telix Pharmaceuticals's total operating income in 2024 was $50.80 million, based on the following breakdown:
  • Total Gross Profit: $315.24 million
  • Total Operating Expenses: $253.55 million
How has Telix Pharmaceuticals revenue changed over the last 2 years?

Over the last 2 years, Telix Pharmaceuticals' total revenue changed from $108.95 million in 2022 to $484.41 million in 2024, a change of 344.6%.

How much debt does Telix Pharmaceuticals have?

Telix Pharmaceuticals' total liabilities were at $586.47 million at the end of 2024, a 234.2% increase from 2023, and a 234.2% increase since 2023.

How much cash does Telix Pharmaceuticals have?

In the past 1 years, Telix Pharmaceuticals' cash and equivalents has ranged from $84.15 million in 2023 to $439.35 million in 2024, and is currently $439.35 million as of their latest financial filing in 2024.

How has Telix Pharmaceuticals' book value per share changed over the last 2 years?

Over the last 2 years, Telix Pharmaceuticals' book value per share changed from 0.00 in 2022 to 1.00 in 2024, a change of 100.2%.



This page (OTCMKTS:TLPPF) was last updated on 4/20/2025 by MarketBeat.com Staff
From Our Partners
Claim Your FREE Protection Guide
In the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...
American Alternative | Sponsored
Elon Reveals Why There Soon Won’t Be Any Money For Social Security
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...
Colonial Metals | Sponsored
Trump’s Top Secret $9 Trillion AI Superweapon
Jeff Brown spotted Nvidia at $1. Now he’s revealing a new AI superweapon — and the Musk-connected stocks that ...
Brownstone Research | Sponsored
My prediction is coming true
We've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...
InvestorPlace | Sponsored
The Crypto Market is About to Change Lives
I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...
Crypto 101 Media | Sponsored
Musk’s AI Masterplan – Our #1 AI Stock to Buy Now
Did Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...
Behind the Markets | Sponsored
Why Elon put $51 million into this
Why Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT Scientists
True Market Insiders | Sponsored
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...
Golden Portfolio | Sponsored